High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma
- 1 January 2005
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 89 (1), 29-34
- https://doi.org/10.1007/s10549-004-1006-8
Abstract
The amount of the immunoreactive protein for the tissue inhibitor of the matrix metalloproteinase-1 (TIMP-1) was studied prospectively from the pretreatment sera of 71 breast carcinoma patients using an enzyme-linked immunoassay (ELISA). The study consisted of patients with a primary breast carcinoma diagnosed between 1988 and 1991. The median follow-up time was more than 10 years, and routine adjuvant treatment was not used in the primary treatment. High TIMP-1 (> 196 ng/ml) was found to correlate with a poor relapse-free survival (RFS) in primary node-negative breast carcinoma. After 10 years of the follow-up only 42% of the patients with a high preoperative serum TIMP-1-level were free of the relapse, whereas 82% of the patients with a low serum TIMP-1 enjoyed a long RFS-time (log rank p =0.009). High serum TIMP-1 also indicated poor RFS (p=0.02) and overall survival (p=0.05) in stage I breast carcinoma. In Kaplan–Meier analysis the RFS was 89% in patients with a low serum level of TIMP-1 compared to 52% in patients with a high serum concentration of TIMP-1. In conclusion, preoperative high serum TIMP-1 levels predict poor outcome in primary breast carcinoma. In multivariate analysis preoperative high serum TIMP-1 increases the risk of relapse 3.4-fold during the first 10 years of follow-up in primary node-negative breast carcinoma.Keywords
This publication has 19 references indexed in Scilit:
- The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases‐1 protein overexpression in breast cancer cellsAPMIS, 2003
- Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinomaBritish Journal of Cancer, 2003
- Matrix Metalloproteinase-2 (MMP-2) in T1–2N0 breast carcinomaBreast Cancer Research and Treatment, 2003
- Expression of proteinases and inhibitors in human breast cancer progression and survivalMolecular Pathology, 2002
- Enhanced mRNA expression of tissue inhibitor of metalloproteinase‐1 (TIMP‐1) in breast carcinomas is correlated with adverse prognosisThe Journal of Pathology, 2002
- Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinomaBritish Journal of Surgery, 2001
- Production of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Breast CarcinomasJapanese Journal of Cancer Research, 1996
- Tissue inhibitor of metalloproteinases (TIMP, aka EPA): Structure, control of expression and biological functionsPharmacology & Therapeutics, 1993
- Cancer metastasis and angiogenesis: An imbalance of positive and negative regulationCell, 1991
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958